Outcomes reporting in clinical trials of Chinese herbal medicine on ulcerative colitis: A systematic review

Xuan Zhang; Lin Zhang; Juan Wang; Lihan Hu; Xuanqi Zhang; Nana Wang; Hanzhi Tan; ChungWah Cheng; Ji Li; Fei Han; Ping Wang; Aiping Lyu; Zhaoxiang Bian

doi:10.1111/jebm.12649

Journal of Evidence-Based Medicine ›› 2024, Vol. 17 ›› Issue (4) : 691 -695. DOI: 10.1111/jebm.12649

LETTER

Outcomes reporting in clinical trials of Chinese herbal medicine on ulcerative colitis: A systematic review

Author information +

History +

PDF

Cite this article

Download citation ▾

Xuan Zhang, Lin Zhang, Juan Wang, Lihan Hu, Xuanqi Zhang, Nana Wang, Hanzhi Tan, ChungWah Cheng, Ji Li, Fei Han, Ping Wang, Aiping Lyu, Zhaoxiang Bian. Outcomes reporting in clinical trials of Chinese herbal medicine on ulcerative colitis: A systematic review. Journal of Evidence-Based Medicine, 2024, 17(4): 691-695 DOI:10.1111/jebm.12649

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	AlsoudD,Verstockt B,FiocchiC,VermeireS. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021; 6(7),589–595.

[2]	SandbornWJ,FeaganBG, D’haensG, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021; 385(14),1280–1291.

[3]	RubinDT,Ananthakrishnan AN,SiegelCA,SauerBG,LongMD. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019; 114(3),384–413.

[4]	ChenJ,ShenB, JiangZ. Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: clinical evidence and potential mechanisms. Front Pharmacol. 2022; 13: 978558.

[5]	ChenK,LouY, ZhuY. Tong Xie Yao Fang: a classic chinese medicine prescription with potential for the treatment of ulcerative colitis. Evid Based Complement Alternat Med. 2021; 2021: 5548764.

[6]	HolleranG,Scaldaferri F,GasbarriniA,CurròD. Herbal medicinal products for inflammatory bowel disease: a focus on those assessed in double-blind randomised controlled trials. Phytother Res. 2020; 34(1),77–93.

[7]	SunY-X,WangX, LiaoX, et al. An evidence mapping of systematic reviews and meta-analysis on traditional Chinese medicine for ulcerative colitis. BMC Complement Med Ther. 2021; 21(1),228.

[8]	ZhangLi,ZhangJ, ChenJ, et al. Clinical research of traditional chinese medicine needs to develop its own system of core outcome sets. Evid Based Complement Alternat Med. 2013; 2013: 202703.

[9]	MaC,HanzelJ, PanaccioneR, et al. CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease. Gastroenterology. 2022; 163(4),950–964.

[10]	MaC,Panaccione R,FedorakRN, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018; 16(5),637–647.e13.

[11]

TurnerD,Ricciuto A,LewisA, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160(5),1570–1583.

[12]	ZhaoH,ZhaoL, WuF,ShenL. Clinical research on traditional Chinese medicine treatment for bacterial vaginosis. Phytother Res. 2021; 35(9),4943–4956.

[13]	ZhaoZH,ZhouY, LiWH,HuangQS,TangZH, LiH. Analysis of traditional Chinese medicine diagnosis and treatment strategies for COVID-19 based on “The Diagnosis and Treatment Program for Coronavirus Disease-2019” from Chinese Authority. Am J Chin Med. 2020; 48(5),1035–1049.

RIGHTS & PERMISSIONS

2024 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.